National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Hematology Am Soc Hematol Educ Program. 2011;2011:257-63. doi: 10.1182/asheducation-2011.1.257.
Despite recent attempts to define and classify patients with marked eosinophilia and features consistent with myeloproliferative disease, areas of controversy remain. These are particularly apparent in situations in which multiple lineages are involved in a clonal process and clinical manifestations are overlapping. Although the introduction of new molecular diagnostics and targeted therapies has begun to clarify the boundaries between some of these disorders, several questions remain with respect to the classification of patients with myeloproliferative hypereosinophilic syndrome (HES) of unknown etiology.
尽管最近有人试图对伴有明显嗜酸性粒细胞增多和骨髓增殖性疾病特征的患者进行定义和分类，但仍存在一些争议领域。在涉及多个谱系的克隆过程和临床表现重叠的情况下，这些问题尤其明显。尽管新的分子诊断和靶向治疗的引入开始澄清其中一些疾病之间的界限，但对于病因不明的骨髓增殖性高嗜酸性粒细胞综合征（HES）患者的分类，仍存在一些问题。
